A new, simple and objective prognostic score for phase i cancer patients

European Journal of Cancer

Volumn 47, Issue 8, 2011, Pages 1152-1160

  Fussenich L M ^a   Desar, I M E ^a   Peters, M E W J ^a   Teerenstra, S ^a   Van Der Graaf, W T A ^a   Timmer Bonte, J N H ^a   Van Herpen, C M L ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Age; Cancer; Clinical outcome; Phase I; Prognostic factors

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CISPLATIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; POTASSIUM; SODIUM;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; DIGESTIVE SYSTEM CANCER; FEMALE; HEAD AND NECK CANCER; HUMAN; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MORTALITY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SARCOMA; THROMBOCYTE COUNT; THROMBOEMBOLISM; URINARY TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE I AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HEMOGLOBINS; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SODIUM; TREATMENT OUTCOME;

EID: 79955541354     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.12.028     Document Type: Article

References (17)

1. H.T. Arkenau, J. Barriuso, and D. Olmos Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 16 2009 2692 2696
2. T. Bachelot, I. Ray-Coquard, and G. Catimel Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials Ann Oncol 11 2 2000 Feb 151 156 (Pubitemid 30148727)
3. N. Penel, J.P. Delord, and M.E. Bonneterre Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics Invest New Drugs 28 1 2010 76 82
4. L. Janisch, R. Mick, and R.L. Schilsky Prognostic factors for survival in patients treated in phase I clinical trials Cancer 74 7 1994 1965 1973 (Pubitemid 24301862)
5. J. Wheler, A.M. Tsimberidou, and D. Hong Survival of patients in a Phase 1 Clinic: the M.D. Anderson Cancer Center experience Cancer 115 5 2009 1091 1099
6. H.T. Arkenau, D. Olmos, and J.E. Ang Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience Br J Cancer 98 6 2008 1029 1033 (Pubitemid 351399798)
7. F.E. Harrel Regression modelling strategies 2010 Springer New York
8. J.N.H. Timmer-Bonte, L.M. Füssenich, and I.M.E. Desar Participation and outcome of older adults in phase I trials: a single institution experience Crit Rev Oncol Hematol 2009 72S1, p109 (Abstract)
9. S.A. Alsirafy, M.Y. Sroor, and M.Z. Al-Shahri Predictive impact of electrolyte abnormalities on the admission outcome and survival of palliative care cancer referrals J Palliat Med 12 2 2009 Feb 177 180
10. A.A. Onitilo, E. Kio, and S.A. Doi Tumor-related hyponatremia Clin Med Res 5 4 2007 Dec 228 237 (Pubitemid 351731692)
11. A.J. Gross, S.M. Steinberg, and J.G. Reilly Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium Cancer Res 53 1 1993 67 74 (Pubitemid 23019378)
12. T. Berghmans, M. Paesmans, and J.J. Body A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis Support Care Cancer 8 3 2000 May 192 197 (Pubitemid 30183035)
13. H. Clarke, and C.J. Pallister The impact of anaemia on outcome in cancer Clin Lab Haematol 27 1 2005 Feb 1 13 (Pubitemid 40293371)
14. N. Penel, M. Vanseymortier, and M.E. Bonneterre Prognostic factors among cancer patients with good performance status screened for phase I trials Invest New Drugs 26 1 2008 53 58
15. C. Han, J.P. Braybrooke, and G. Deplanque Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents Br J Cancer 89 7 2003 1166 1171 (Pubitemid 37363397)
16. Olmos D. Multi-institutional prognostic factor analysis of patients (pts) enrolled in phase I (Ph I) oncology trials: Can pts selection be improved. J Clin Oncol (Meeting Abstracts) 28, 2581. 2010.
17. S. Postel-Vinay, H.T. Arkenau, and D. Olmos Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? Br J Cancer 100 9 2009 1373 1378